Cortica, a San Diego, CA-based physician-led autism services company, raised $75M in funding and acquired Springtide Child Development.
The round was led by Deerfield Management and Optum Ventures. Additional new investors included RA Capital Management and Echo Health Ventures, alongside existing investors Longitude Capital, .406 Ventures, Questa Capital, Ajax Health, Aperture Venture Partners, and the Autism Impact Fund.
In the acquisition of Springtide, a premier integrated data-driven autism provider in the Northeast, Springtide’s investors have rolled their equity entirely into Cortica. The deal includes six autism centers in Connecticut and Massachusetts.
The company has also acquired the Melmed Center, a developmental pediatrics clinical and research group based in Arizona.
Led by CEO Neil Hattangadi, Cortica is a physician-led autism services company that blends neurology, research-based therapies, and technology into comprehensive care programs for families that search diagnoses and therapies for their children.
Since its founding in 2017, the company has grown into an organization with more than 1,600 employees, including pediatric neurologists, developmental pediatricians, epileptologists, pediatric nurse practitioners, speech language pathologists, occupational therapists, physical therapists, music therapists, board certified behavior analysts, registered behavior technicians, social workers, marriage and family therapists, care navigators, and more. They have built the Cortica Innovation Network, a team of researchers and physicians who conduct outcomes research and are a global leader in clinical trial recruitment. Through organic growth and new acquisitions, the company will serve more than 10,000 neurodivergent children and their families this year.
The company now owns and operates 23 integrated autism centers across the country.